Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
+0.110 (4.51%)
At close: Jun 21, 2024, 4:00 PM
-0.020 (-0.78%)
After-hours: Jun 21, 2024, 7:46 PM EDT

Allogene Therapeutics Revenue

Allogene Therapeutics had revenue of $65.00K in the twelve months ending March 31, 2024, down -48.00% year-over-year. Revenue in the quarter ending March 31, 2024 was $22.00K, a -26.67% decrease year-over-year. In the year 2023, Allogene Therapeutics had annual revenue of $95.00K, a decrease of -39.10%.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
532.40M USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 20200--
Dec 31, 20190--
Dec 31, 20180--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Clover Health Investments 1.85B
Cross Country Healthcare 1.78B
SI-BONE 144.05M
Quanterix 125.98M
Y-mAbs Therapeutics 84.50M
Contineum Therapeutics 50.00M
Revenue Rankings